Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 2/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.37 |
| ▸ | LMNA | P02545 | 2/20 | 0.37 |
| ▸ | GLA | P06280 | 1/20 | 0.36 |
| ▸ | SRC | P12931 | 2/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.36 |
| ▸ | SMYD3 | Q9H7B4 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.35 |
| ▸ | NPC1 | O15118 | 2/20 | 0.35 |
| ▸ | MITF | O75030 | 2/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | RAB9A | P51151 | 1/20 | 0.35 |
| ▸ | HTT | P42858 | 1/20 | 0.35 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | SCD | O00767 | 1/20 | 0.33 |
| ▸ | CA5A | P35218 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | TP53 | P04637 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24621692 | 0.87 | TSHR (0.40) | TSHRALDH1A1LMNAGLASRC | |
| SCHEMBL12418868 | 0.83 | KDM4E (0.40) | TSHRALDH1A1LMNAGLASRC | |
| SCHEMBL23675961 | 0.83 | MAPK1 (0.37) | TSHRALDH1A1LMNAGLASRC | |
| SCHEMBL18307624 | 0.80 | GLA (0.46) | TSHRALDH1A1LMNAGLASRC | |
| SCHEMBL12392022 | 0.80 | NR1H4 (0.40) | ALDH1A1LMNAGLASMN1; SMN2NR1H4 | |
| SCHEMBL23278768 | 0.78 | TSHR (0.41) | TSHRALDH1A1LMNASRCMAPK1 | |
| SCHEMBL25446383 | 0.78 | NR1H4 (0.38) | ALDH1A1LMNAGLASMN1; SMN2MAPT | |
| SCHEMBL25446432 | 0.74 | HSP90AB1 (0.46) | TSHRALDH1A1LMNAKMT2ANPC1 | |
| SCHEMBL3279219 | 0.73 | MME (0.37) | — | |
| SCHEMBL12391978 | 0.73 | MAPT (0.42) | ALDH1A1LMNAMAPTNR1H4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230365609-A1 | HIGHLY POTENT MULTIMERIC E-SELECTIN ANTAGONISTS | GLYCOMIMETICS, INC. (US) | 2023-11-16 | — | — | US | disclosed |
| US-20230365609-A1 | HIGHLY POTENT MULTIMERIC E-SELECTIN ANTAGONISTS | GLYCOMIMETICS, INC. (US) | 2023-11-16 | — | — | US | disclosed |
| US-11780873-B2 | Highly potent multimeric e-selectin antagonists | GLYCOMIMETICS, INC. (US) | 2023-10-10 | — | — | US | disclosed |
| US-11780873-B2 | Highly potent multimeric e-selectin antagonists | GLYCOMIMETICS, INC. (US) | 2023-10-10 | — | — | US | disclosed |
| US-20230218649-A1 | COMPOSITIONS AND METHODS FOR OVERCOMING MICROENVIRONMENT-MEDIATED RESISTANCE VIA E-SELECTIN TARGETING | GLYCOMIMETICS, INC. (US) | 2023-07-13 | — | — | US | disclosed |
| US-20230218649-A1 | COMPOSITIONS AND METHODS FOR OVERCOMING MICROENVIRONMENT-MEDIATED RESISTANCE VIA E-SELECTIN TARGETING | GLYCOMIMETICS, INC. (US) | 2023-07-13 | — | — | US | disclosed |
| US-20230165882-A1 | COMPOUNDS AND METHODS FOR REDUCTION OF CANCER CELL BURDEN AND PROTECTION OF NORMAL HEMATOPOIESIS | GLYCOMIMETICS, INC. (US) | 2023-06-01 | — | — | US | disclosed |
| US-20230165882-A1 | COMPOUNDS AND METHODS FOR REDUCTION OF CANCER CELL BURDEN AND PROTECTION OF NORMAL HEMATOPOIESIS | GLYCOMIMETICS, INC. (US) | 2023-06-01 | — | — | US | disclosed |
| US-20230147312-A1 | TREATMENT OF ACUTE RESPIRATORY DISTRESS SYNDROME AND RELATED CONDITIONS WITH ANTAGONISTS OF E-SELECTIN | GLYCOMIMETICS, INC. (US) | 2023-05-11 | — | — | US | disclosed |
| US-20230147312-A1 | TREATMENT OF ACUTE RESPIRATORY DISTRESS SYNDROME AND RELATED CONDITIONS WITH ANTAGONISTS OF E-SELECTIN | GLYCOMIMETICS, INC. (US) | 2023-05-11 | — | — | US | disclosed |
| US-20220220144-A1 | MULTIMERIC PAN-SELECTIN ANTAGONISTS | GLYCOMIMETICS, INC. (US) | 2022-07-14 | — | — | US | disclosed |
| US-20210323990-A1 | HIGHLY POTENT MULTIMERIC E-SELECTIN ANTAGONISTS | GLYCOMIMETICS, INC. (US) | 2021-10-21 | — | — | US | disclosed |
| US-11072625-B2 | Highly potent multimeric e-selectin antagonists | GLYCOMIMETICS, INC. (US) | 2021-07-27 | — | — | US | disclosed |
| US-20190233458-A1 | HIGHLY POTENT MULTIMERIC E-SELECTIN ANTAGONISTS | GLYCOMIMETICS, INC. (US) | 2019-08-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210323990-A1 | HIGHLY POTENT MULTIMERIC E-SELECTIN ANTAGONISTS | SELE, SELP, SELPLG | TSHR 2178/4885ALDH1A1 759/4885LMNA 1882/4885 |
| US-20190233458-A1 | HIGHLY POTENT MULTIMERIC E-SELECTIN ANTAGONISTS | SELE, SELP, SELPLG | TSHR 2178/4885ALDH1A1 759/4885LMNA 1882/4885 |
| US-11072625-B2 | Highly potent multimeric e-selectin antagonists | SELE, SELP, SELPLG | TSHR 1887/4885ALDH1A1 773/4885LMNA 2271/4885 |
| US-20230218649-A1 | COMPOSITIONS AND METHODS FOR OVERCOMING MICROENVIRONMENT-MEDIATED RESISTANCE VIA E-SELECTIN TARGETING | SELE, SELPLG, MCL1 | TSHR 4318/4885ALDH1A1 1037/4885LMNA 2588/4885 |
| US-20230165882-A1 | COMPOUNDS AND METHODS FOR REDUCTION OF CANCER CELL BURDEN AND PROTECTION OF NORMAL HEMATOPOIESIS | FLT3, SELE, SELL | TSHR 3058/4885ALDH1A1 1066/4885LMNA 3544/4885 |
| US-11780873-B2 | Highly potent multimeric e-selectin antagonists | SELE, SELP, SELPLG | TSHR 1887/4885ALDH1A1 773/4885LMNA 2271/4885 |
| US-20220220144-A1 | MULTIMERIC PAN-SELECTIN ANTAGONISTS | SELE, SELP, BSG | TSHR 4014/4885ALDH1A1 1387/4885LMNA 1733/4885 |
| US-20230147312-A1 | TREATMENT OF ACUTE RESPIRATORY DISTRESS SYNDROME AND RELATED CONDITIONS WITH ANTAGONISTS OF E-SELECTIN | SELP, SELE, SELPLG | TSHR 1769/4885ALDH1A1 1201/4885LMNA 1616/4885 |
| US-20230365609-A1 | HIGHLY POTENT MULTIMERIC E-SELECTIN ANTAGONISTS | SELE, SELP, SELPLG | TSHR 2178/4885ALDH1A1 759/4885LMNA 1882/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.